In the last trading session, 2.18 million Fate Therapeutics Inc (NASDAQ:FATE) shares changed hands as the company’s beta touched 2.25. With the company’s per share price at $1.42 changed hands at -$0.12 or -8.09% during last session, the market valuation stood at $161.73M. FATE’s last price was a discount, traded about -521.83% off its 52-week high of $8.83. The share price had its 52-week low at $1.04, which suggests the last value was 26.76% up since then.
Analysts gave the Fate Therapeutics Inc (FATE) stock a consensus recommendation rating of Buy, calculated at a mean rating of 2.44. If we narrow down to specifics, the data shows that 1 out of 8 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended FATE as a Hold, 5 felt it is a Buy and 0 rated the stock as Underweight. Fate Therapeutics Inc’s EPS for the current quarter is expected to be -0.43.
Fate Therapeutics Inc (NASDAQ:FATE) trade information
Instantly FATE was in red as seen at the end of in last trading. With action 11.81%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -13.94%, with the 5-day performance at 11.81% in the green. However, in the 30-day time frame, Fate Therapeutics Inc (NASDAQ:FATE) is 5.97% up.
The consensus price target for the stock as assigned by Wall Street analysts is 5, meaning bulls need an upside of 71.6% from its current market value. According to analyst projections, FATE’s forecast low is 5 with 5 as the target high. To hit the forecast high, the stock’s price needs a -252.11% plunge from its current level, while the stock would need to soar -252.11% for it to hit the projected low.
Fate Therapeutics Inc (FATE) estimates and forecasts
Year-over-year growth is forecast to reach -78.59% down from the last financial year.
Consensus estimates given by 12 financial analysts project the company’s revenue in the current quarter to hit an average of 1.57M. 9 analysts are of the opinion that Fate Therapeutics Inc’s revenue for the current quarter will be 1.24M. The company’s revenue for the corresponding quarters a year ago was 1.68M and 1.93M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -6.40%. The estimates for the next quarter sales put growth at -35.45%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -6.65%. The 2025 estimates are for Fate Therapeutics Inc earnings to increase by 0.43%, but the outlook for the next 5-year period is at 1.90% per year.
Fate Therapeutics Inc (NASDAQ:FATE)’s Major holders
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 10.4544% or 10.57 million shares worth $34.67 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 3.05 shares estimated at $4.33 million under it, the former controlled 2.68% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.46% of the shares, roughly 2.8 shares worth around $3.98 million.
